Bristol-myers Squibb Compnay

Joan Carboni

Marco Gottardis

Ray Camphausen

Stuart Emanuel

Ricardo Attar

Martin C Wright

Linda Engle

Eric Steven Furfine

Ginger Chao Rakestraw

H Nicholas Marsh

Irvith M Carvajal

Francis Lee

David K Bol

Fei Huang

Xia Han

Ashok Ramesh Dongre

Tai W Wong

Warren Hurlburt

Ginger Chao

Ronald B Rowley

Rameh Hafezi

Jiwen Chen

Douglas Michael Robinson

Gayle M Wittenberg

Marco M Gottardis

Ricardo M Attar

The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.

Bispecific EGFR/IGFIR binding molecules

The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.

Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins

Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules

Multivalent fibronectin based scaffold domain proteins

Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules

IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.

Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators

A transgenic non-human mammal whose germ cells and somatic cells contain a constructively activated tyrosine kinase receptor introduced into the mammal, or an ancestor of the mammal, at an embryonic stage. The transgenic non-human mammals can be used as ligand-independent in vivo models for the identification and development of selective tyrosine kinase modulators for the treatment of cancer.

Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors

Growing community of inventors

Yardley, PA, United States of America

Joan Carboni